The Federal Drug Administration (FDA) has announced the recall of over 580,000 bottles of a blood pressure medication due to potential cancer risks. This recall was initiated by Teva Pharmaceuticals USA, a New Jersey-based company, along with distributor Amerisource Health Services.
Details of the Recall
The voluntary recall affects various strengths of prazosin capsules, specifically prazosin hydrochloride. These capsules are available in the following doses:
- 1 mg
- 2 mg
- 5 mg
Prazosin is primarily used to relax blood vessels, enhancing blood flow. It is also prescribed for nightmares and other sleep issues associated with post-traumatic stress disorder (PTSD).
Potential Health Risks
The FDA designated the recalled lots as a Class II risk. This classification indicates the use of the medication may lead to temporary health issues. The recall stems from the discovery of nitrosamine impurities in the medication. These impurities are potentially carcinogenic, posing serious health concerns.
The formation of these chemicals can occur during the manufacturing or storage processes of pharmaceuticals.
Company Response
As of now, Teva Pharmaceuticals has not provided comments regarding the recall. For consumers using this medication, it is crucial to stay informed about any developments related to their prescriptions.
Patients are advised to consult their healthcare providers for alternative treatments or to discuss any concerns following this recall.
